Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates solid financial performance, particularly with strong margins and EPS growth. The launch of the AI platform and strategic acquisitions like ACD/Labs are positive catalysts. The Q&A highlights robust customer engagement and strong SaaS growth, despite short-term organic growth challenges. The divestiture strategy is seen as a positive move, enhancing long-term margins and reducing risk exposure. Although there are some uncertainties, the overall sentiment remains positive, with potential for stock price appreciation in the short term.
Key Financial Performance
Total Company Organic Growth 3% growth year-over-year, demonstrating resilience and strength of the business.
Adjusted Operating Margins 23.6%, above the 23% outlook, driven by better-than-anticipated revenue and margin performance.
Adjusted Earnings Per Share (EPS) $1.06, above the $1.02 to $1.04 outlook, due to revenue and margin upside.
Revenue from Immunodiagnostics Business in China Represented approximately 6% of total company revenue last year; divestiture planned due to persistent policy-induced headwinds and declining customer demand.
Pro Forma Organic Growth (excluding China Immunodiagnostics) 6% growth year-over-year, reflecting the removal of a lower growth, lower margin business.
Pro Forma Adjusted Operating Margins (excluding China Immunodiagnostics) 24%, an improvement due to the divestiture of the China immunodiagnostics business.
Reproductive Health Business Growth Low double digits organically, driven by newborn screening and Genomics England contract contributions.
Life Sciences Segment Organic Growth 3% growth year-over-year, with low single-digit growth in reagents and mid-single-digit growth in instrumentation.
Diagnostics Segment Organic Growth 4% growth year-over-year, with strong performance in reproductive health and immunodiagnostics outside China.
Free Cash Flow Conversion 97% conversion of adjusted net income, reflecting robust cash flow generation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-driven software innovations: Introduced Xynthetica, an AI models as a service platform, BioDesign, a cloud-native molecular design platform for biologics development, and announced LabGistics, an AI-first drug discovery to drug development workflow offering.
Instruments innovation: Launched Opera Phenix OptIQ system with enhanced confocal imaging capabilities, advanced 3D cell analysis, and automated phenotypic profiling.
China market strategy: Decided to divest the immunodiagnostics business in China due to policy-induced headwinds and focus on higher growth areas like Life Sciences.
Geographic performance: Double-digit growth in Europe, low single-digit growth in the Americas, and mid-single-digit decline in APAC due to challenges in China.
Operational efficiency initiatives: Implementation underway, expected to be completed midyear, contributing to margin expansion in the second half of 2026 and robust margin growth in early 2027.
AI adoption internally: Deployed multiple leading LLMs globally, achieving high employee adoption rates and accelerating software delivery at reduced costs.
Divestiture of China immunodiagnostics business: Strategic decision to divest this business, representing 6% of total revenue, to focus on higher return areas and improve financial metrics.
Focus on AI and Life Sciences: Positioning to capitalize on AI-driven demand in life sciences, emphasizing consumables, instruments, and software for validation of AI discoveries.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China Immunodiagnostics Business: The company is divesting its immunodiagnostics business in China due to persistent policy-induced headwinds, declining customer demand, and pricing challenges. Maintaining this business would require substantial investments in localizing manufacturing, supply chains, and regulatory capabilities, which would divert resources from higher-return initiatives.
Market and Policy Challenges in China: The healthcare market in China, particularly diagnostics, faces ongoing policy-induced challenges that impact customer demand and pricing dynamics. These challenges are expected to persist in the medium term, creating uncertainty and financial pressure.
Pharma and Biotech Spending Environment: Customer behavior in the pharma and biotech sectors remains measured, with spending influenced by budget cycles. While there are early signs of improvement, the environment remains uncertain.
Academic and Government Funding: Although there are promising developments in academic and government funding, the company remains cautious due to the potential for rapid changes in policies and regulations.
Global Birth Rate Trends: The reproductive health business faces challenges from declining global birth rates, which could impact growth in the newborn screening segment.
Foreign Exchange (FX) Impact: FX fluctuations have created headwinds, reducing expected revenue growth contributions from 100 basis points to 50 basis points.
Operational Efficiency Initiatives: The company is implementing operational efficiency initiatives, but these will not fully contribute to financial performance until mid-2026, creating a lag in realizing benefits.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Divestiture of Immunodiagnostics Business in China: Revvity plans to divest its immunodiagnostics business in China, which represented approximately 6% of total company revenue in 2025. This decision is expected to improve 2026 organic growth by 100 basis points and enhance operating margins by 30 basis points. The transaction is anticipated to close by the end of 2027, with Revvity retaining a minority interest in the new company.
2026 Financial Guidance: Revvity expects 2026 organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share (EPS) of $5.20 to $5.30. This includes a $0.20 reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution.
Market Trends and End Markets: Pharma and biotech spending showed modest improvement in Q1 2026, with early indicators of future improvement. Academic and government spending also showed positive trends, with mid-single-digit growth in Q1. However, the company remains cautious about sustained improvement in these markets.
AI and Software Innovation: Revvity anticipates significant future demand for its consumables, instruments, and software driven by AI adoption in life sciences. The company plans to launch LabGistics, an AI-first drug discovery workflow, later in 2026. AI is expected to create a virtuous cycle of innovation and demand for laboratory tools.
Operational Efficiency Initiatives: Revvity's operational efficiency initiatives are expected to be fully implemented by mid-2026, contributing to margin expansion in the second half of 2026 and positioning the company for robust margin growth in early 2027.
Capital Deployment and Financial Position: Revvity plans to pay off $600 million in Eurobond debt by mid-2026, reducing gross leverage to below 3x by year-end. The company expects improved cash flow conversion following the divestiture of the China immunodiagnostics business.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Revvity repurchased $86 million worth of shares in the first quarter of 2026. This repurchase contributed to an average of 111.9 million diluted shares in the quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the recent conversations with customers regarding the software SaaS piece and the trends?
A:Prahlad Singh mentioned that customer engagement and excitement remain high, particularly with the Lilly TuneLab's partnership and the launches of Xynthetica, BioDesign, and LabGistics. Maxwell Krakowiak added that organic growth is not the best measure for this business, but APV showed strong double digits in Q1, with SaaS and ARR growth north of 30%. Organic growth for the full year is expected to be mid-single digits, with a decline of approximately 20% in Q2 due to tougher comps, but high teens growth is expected in the second half.
Q:Can you provide more color on the reagents business and recent biotech funding?
A:Prahlad Singh characterized the reagents business as positively stable, with better performance in Q1 and revenue up mid-single digits. There are signs of improvement in both instruments and reagents, building optimism in this market.
Q:Does the China Dx divestiture change your appetite for further M&A and capital deployment?
A:Prahlad Singh stated that the divestiture aligns with their portfolio transformation strategy, reducing exposure to the challenging China Diagnostics market. The company will continue to be acquisitive and opportunistic with share buybacks, leveraging proceeds from the divestiture.
Q:What steps are being taken for AI corporate implementation, and how will it impact margins?
A:Prahlad Singh highlighted structured AI adoption, including rolling out leading LLMs globally, achieving high adoption rates, and doing so at a fraction of traditional costs. This is expected to improve productivity, efficiency, and cost savings in the mid- to long-term.
Q:Can you unpack the strength in reproductive health and its outlook?
A:Maxwell Krakowiak noted strong Q1 performance with double-digit growth, driven by reagents, instrument placements, and the Genomics England partnership. The full-year contribution from GEL is expected to be $20 million. Despite challenging birth rates, the business benefits from new assays and geographic expansion.
Q:Can you provide details on the ImmunoDx business divestiture in China?
A:Maxwell Krakowiak mentioned a letter of intent to divest the business, with definitive agreements expected in Q2 and closure in 2027. The divestiture is led by an internal management group, and the company is confident in its completion.
Q:Why does the annual guide imply a step down in organic growth despite strong Q1 performance?
A:Maxwell Krakowiak explained that the annual guidance of 3%-4% organic growth reflects conservatism for Life Science Solutions and Diagnostics in the second half. Q1 saw 6% growth, and Q2 is guided at 2%-3%, averaging 4% in H1. Upside potential exists if market conditions improve.
Q:Why was organic growth guidance raised while EPS guidance was lowered?
A:Maxwell Krakowiak clarified that the 100 bps organic growth increase is due to removing the China immunodiagnostics business. The EPS guidance does not include proceeds from the divestiture, which will close in 2027.
Q:What is the impact of the China divestiture on future years' margins and growth?
A:Prahlad Singh and Maxwell Krakowiak stated that the divestiture fortifies the long-range plan, removes overhang, and improves margins. Cost efficiency initiatives will offset earnings dilution, and the new baseline margin is 28.4%.
Q:What are the moving pieces in the Q2 guidance?
A:Maxwell Krakowiak stated that the 2%-3% organic growth guidance reflects the removal of the China IDx business. Life Sciences is expected to be flat, with low single-digit growth in Life Science Solutions and a 20% decline in software. Diagnostics is expected to grow mid- to high single digits.
Q:What signals are being seen in the bio/pharma market?
A:Prahlad Singh noted modest improvements in instruments and reagents, with low single-digit growth in Q1 from pharma/biotech customers. Optimism exists as customers move in the right direction.
Q:What are the drivers of operating margin improvement in 2026?
A:Maxwell Krakowiak explained that Q1 margins benefited from strong incrementals. Margins are expected to improve sequentially due to seasonal revenue increases, cost productivity initiatives, and operational efficiencies.
Q:What is the outlook for 2027 margins and capital deployment?
A:Maxwell Krakowiak mentioned that cost actions completed in 2026 will benefit 2027 margins. Prahlad Singh stated that M&A will focus on filling portfolio gaps, with share buybacks being a significant opportunity.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the dilution impact of the China divestiture in future years, stating only high-level strategic benefits and general confidence in cost efficiency initiatives to offset earnings dilution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI adoption
AI discovery
AI model
BioDesign
Internet
OptIQ
Singh
allocation
approach
base
biology
buyer
cell
compound
core
cycle
decision
discussion
divestiture
drug
employee
example
experimentation
forma basis
fraction
immunodiagnostics China
infrastructure
insight
midyear
move
phase
policy
research
resource
risk
strength
success
system
trajectory
validation work
value creation
RVTY Transcript
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call indicates solid financial performance, particularly with strong margins and EPS growth. The launch of the AI platform and strategic acquisitions like ACD/Labs are positive catalysts. The Q&A highlights robust customer engagement and strong SaaS growth, despite short-term organic growth challenges. The divestiture strategy is seen as a positive move, enhancing long-term margins and reducing risk exposure. Although there are some uncertainties, the overall sentiment remains positive, with potential for stock price appreciation in the short term.
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-2
RVTY Slides
RVTY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
